Dishman Carbogen Amcis Ltd submitted its investor presentation on audited Q4FY26 and FY26 results to BSE and NSE per SEBI LODR Regulations 30 and 51.
Q4FY26 net revenue grew 18.9% YoY to ₹8,514 mn, while full-year FY26 revenue reached ₹29,319 mn, up 8.1% from FY25.
FY26 EBITDA margin improved to 19.3% from 17.3% in FY25, driven by growth in CDMO and Marketable Molecules segments.
Net debt excluding lease liabilities stood at CHF 146.80 mn as of March 31, 2026, down from CHF 157.6 mn a year ago.